MICROBOT MEDICAL INC
MBOTNASDAQTrading Snapshot
- Day Range
- $1.73 – $1.76
- 52-Week Range
- $1.60 – $4.67
- Volume
- $2.00B
- Avg Volume
- $2.39B
- Shares Outstanding
- 45.6M
- Next Earnings
- Sep 5, 2026
Fundamentals Snapshot
- Annual Revenue
- $346,000
- Last Q Revenue
- $241,000
- P/E Ratio
- -6.4
- P/S Ratio
- 221.3x
- EPS (TTM)
- $-0.15
- Dividend Yield
- 0.00%
Why Investors Own MBOT
- ✓High-growth profile — revenue up +14.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 42% gross margin and 21% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About MICROBOT MEDICAL INC
Microbot Medical Inc. operates as a pre-clinical stage medical device company, concentrating its efforts on the research, design, and development of robotic instruments for endoluminal surgery, specifically targeting the field of minimally invasive procedures. Leveraging its proprietary micro-robotic technologies, which include ViRob, TipCAT, CardioSert, and Liberty, the company is actively developing several key products. These include a Self-Cleaning Shunt intended for the treatment of hydrocephalus and normal pressure hydrocephalus, as well as a single-use robotic system designed for various endovascular interventional applications. Additionally, Microbot Medical maintains a robust, multi-generational product pipeline. Its global intellectual property portfolio is substantial, encompassing 42 granted or allowed patents and an additional 23 patent applications currently under review. The company also benefits from a strategic collaboration agreement with Stryker Corporation, focusing on joint technology development. Established in 2010, Microbot Medical Inc. is headquartered in Hingham, Massachusetts.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Microbot Medical Q2 EPS $(0.08), Inline, Sales $241.000K Miss $340.000K Estimate
Microbot Medical (NASDAQ:MBOT) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 20 percent increase over losses of $(0.10) per share from the same period last year. The
Microbot Medical® Among Featured Companies Showcasing Novel Robotic Technologies and Digital Surgery Applications at the Society of Robotic Surgery Annual Meeting
Company CEO has been a featured presenter at several recent industry events on the emergence of endovascular robotics as expert speaking opportunities raising profile of the Company throughout medtech marketHINGHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, will be participating at this year’s Society of Robotic Surgery (SRS) annual meeting, being held from July 23-26, in Fort L